CN103562723B - 用于识别肿瘤细胞的标记、方法及其试剂盒 - Google Patents
用于识别肿瘤细胞的标记、方法及其试剂盒 Download PDFInfo
- Publication number
- CN103562723B CN103562723B CN201280021095.4A CN201280021095A CN103562723B CN 103562723 B CN103562723 B CN 103562723B CN 201280021095 A CN201280021095 A CN 201280021095A CN 103562723 B CN103562723 B CN 103562723B
- Authority
- CN
- China
- Prior art keywords
- combination
- cell
- expression
- cancer
- prognosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0695—Stem cells; Progenitor cells; Precursor cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
Abstract
Description
Claims (14)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2835/CHE/2010 | 2011-03-27 | ||
IN2835CH2010 | 2011-03-27 | ||
PCT/IB2012/051427 WO2012131564A1 (en) | 2011-03-27 | 2012-03-26 | Markers for identifying tumor cells, methods and kit thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103562723A CN103562723A (zh) | 2014-02-05 |
CN103562723B true CN103562723B (zh) | 2017-04-26 |
Family
ID=46877646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280021095.4A Active CN103562723B (zh) | 2011-03-27 | 2012-03-26 | 用于识别肿瘤细胞的标记、方法及其试剂盒 |
Country Status (8)
Country | Link |
---|---|
US (2) | US8772455B2 (zh) |
EP (1) | EP2691776A4 (zh) |
JP (1) | JP2014515821A (zh) |
KR (1) | KR101621036B1 (zh) |
CN (1) | CN103562723B (zh) |
AU (1) | AU2012235767B2 (zh) |
SG (1) | SG193630A1 (zh) |
WO (1) | WO2012131564A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015023493A2 (pt) | 2013-03-15 | 2017-10-10 | Varian Med Sys Inc | método para tratamento de um tumor, método para identificar um sujeito, método para a seleção de um tratamento, e, kit |
CN105339390A (zh) * | 2013-04-29 | 2016-02-17 | Ogd2药物 | 靶向o-乙酰化的gd2神经节苷脂作为针对癌症干细胞的新型治疗和诊断策略 |
JP6841609B2 (ja) | 2015-07-10 | 2021-03-10 | 3スキャン インコーポレイテッド | 組織学的染色の空間的多重化 |
FR3044680B1 (fr) * | 2015-12-02 | 2017-12-22 | Univ Limoges | Methode de detection de cellules souches cancereuses |
MY195697A (en) * | 2016-05-24 | 2023-02-05 | Oncostem Pte Ltd | Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof |
CN106053172B (zh) * | 2016-06-03 | 2018-10-30 | 浙江世纪康大医疗科技股份有限公司 | 一种edta抗原修复液 |
US10166406B2 (en) | 2017-02-24 | 2019-01-01 | Varian Medical Systems International Ag | Radiation treatment planning and delivery using collision free regions |
CN115429881A (zh) * | 2022-09-02 | 2022-12-06 | 中国医学科学院基础医学研究所 | 铁螯合剂治疗β-连环蛋白活化突变的肿瘤 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101088089A (zh) * | 2004-02-23 | 2007-12-12 | 鹿特丹伊拉斯姆斯大学医疗中心 | 通过基因表达图形对急性粒细胞性白血病进行分类、诊断和预后 |
CN101583624A (zh) * | 2006-09-29 | 2009-11-18 | 昂考梅德药品有限公司 | 用于诊断和治疗癌症的组合物和方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100035240A1 (en) * | 2004-08-10 | 2010-02-11 | Cardiff Biologicals Limited | Methods and kit for the prognosis of breast cancer |
WO2007075672A2 (en) * | 2005-12-23 | 2007-07-05 | Lankenau Institute For Medical Research | Prognostic cancer markers |
WO2007114896A2 (en) | 2006-03-31 | 2007-10-11 | Ordway Research Institute | Prognostic and diagnostic method for cancer therapy |
EA018260B1 (ru) * | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
US7968169B2 (en) * | 2007-08-07 | 2011-06-28 | The Boeing Company | Compound contoured composite beams and fabrication methods |
WO2009126310A2 (en) * | 2008-04-10 | 2009-10-15 | Massachusetts Institute Of Technology | Methods for identification and use of agents targeting cancer stem cells |
WO2011007853A1 (ja) * | 2009-07-14 | 2011-01-20 | リンク・ジェノミクス株式会社 | 癌特異的アイソフォームに対するモノクローナル抗体 |
WO2011113047A2 (en) * | 2010-03-12 | 2011-09-15 | The Johns Hopkins University | Compositions and methods for characterizing breast cancer |
-
2012
- 2012-03-26 WO PCT/IB2012/051427 patent/WO2012131564A1/en active Application Filing
- 2012-03-26 AU AU2012235767A patent/AU2012235767B2/en active Active
- 2012-03-26 SG SG2013072483A patent/SG193630A1/en unknown
- 2012-03-26 JP JP2014501759A patent/JP2014515821A/ja active Pending
- 2012-03-26 EP EP12765275.8A patent/EP2691776A4/en not_active Withdrawn
- 2012-03-26 CN CN201280021095.4A patent/CN103562723B/zh active Active
- 2012-03-26 KR KR1020137028327A patent/KR101621036B1/ko active IP Right Grant
- 2012-03-27 US US13/431,919 patent/US8772455B2/en active Active
-
2014
- 2014-06-13 US US14/304,432 patent/US20140295459A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101088089A (zh) * | 2004-02-23 | 2007-12-12 | 鹿特丹伊拉斯姆斯大学医疗中心 | 通过基因表达图形对急性粒细胞性白血病进行分类、诊断和预后 |
CN101583624A (zh) * | 2006-09-29 | 2009-11-18 | 昂考梅德药品有限公司 | 用于诊断和治疗癌症的组合物和方法 |
Non-Patent Citations (3)
Title |
---|
Expression of CD133,PAX2,ESA,and GPR30 in invasive ductal breast carcinomas;Liu qun,et al.;《Chinese Medical Journal》;20091231;第122卷(第22期);第2763-2769页 * |
Multiple Lineages of Human Breast Cancer Stem/Progenitor Cells Identified by Profiling with Stem Cell Markers;Wendy W. Hwang-Verslues,et al.;《Plos One》;20091231;第4卷(第12期);第2页"Breast Cancer Cell Lines Heterogeneously Expressed Stem Cell Markers"部分,表1,附图5 * |
微环境调控肾上腺皮质癌干细胞CD44、CXCR4、CD133和ABCG2表达的实验研究;罗佐杰;《中国博士学位论文全文数据库 医药卫生科技辑》;20100815;参见摘要,第43-44页第1.2.2.2节 * |
Also Published As
Publication number | Publication date |
---|---|
EP2691776A1 (en) | 2014-02-05 |
WO2012131564A1 (en) | 2012-10-04 |
AU2012235767A1 (en) | 2013-11-07 |
JP2014515821A (ja) | 2014-07-03 |
US20120244556A1 (en) | 2012-09-27 |
CN103562723A (zh) | 2014-02-05 |
EP2691776A4 (en) | 2015-04-15 |
US20140295459A1 (en) | 2014-10-02 |
AU2012235767B2 (en) | 2016-02-04 |
KR101621036B1 (ko) | 2016-05-13 |
SG193630A1 (en) | 2013-10-30 |
US8772455B2 (en) | 2014-07-08 |
KR20140015500A (ko) | 2014-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103562723B (zh) | 用于识别肿瘤细胞的标记、方法及其试剂盒 | |
Kim et al. | EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number | |
West et al. | MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation | |
Akervall et al. | A novel panel of biomarkers predicts radioresistance in patients with squamous cell carcinoma of the head and neck | |
Riener et al. | Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas | |
Zucali et al. | Insulin‐like growth factor‐1 receptor and phosphorylated AKT‐serine 473 expression in 132 resected thymomas and thymic carcinomas | |
Pusztaszeri et al. | MYB immunostaining is a useful ancillary test for distinguishing adenoid cystic carcinoma from pleomorphic adenoma in fine‐needle aspiration biopsy specimens | |
Lodhia et al. | Prioritizing therapeutic targets using patient-derived xenograft models | |
Edden et al. | The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma | |
Buckup et al. | Plectin is a regulator of prostate cancer growth and metastasis | |
Matsuoka et al. | The tumour stromal features are associated with resistance to 5‐FU‐based chemoradiotherapy and a poor prognosis in patients with oral squamous cell carcinoma | |
Tzanakis et al. | Prognostic significance of p53 and Ki67 proteins expression in Greek gastric cancer patients | |
Miller et al. | PD‐L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer | |
Knoll et al. | The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker | |
Krawczyk et al. | HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor | |
Cumberbatch et al. | Identification of a subset of human non–small cell lung cancer patients with high PI3Kβ and low PTEN expression, more prevalent in squamous cell carcinoma | |
Yang et al. | C23 protein meditates bone morphogenetic protein-2-mediated EMT via up-regulation of Erk1/2 and Akt in gastric cancer | |
Bose et al. | Bax expression measured by AQUAnalysis is an independent prognostic marker in oral squamous cell carcinoma | |
Fleischmann et al. | High‐level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients | |
Fraune et al. | Upregulation of PTTG1 is associated with poor prognosis in prostate cancer | |
Alves et al. | Downregulation of AGR 2, p21, and cyclin D and alterations in p53 function were associated with tumor progression and chemotherapy resistance in epithelial ovarian carcinoma | |
Dalbagni et al. | Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder | |
Ahmed et al. | Akt and Hippo pathways in Ewing's sarcoma tumors and their prognostic significance | |
Beppu et al. | Expression of cancer/testis antigens in salivary gland carcinomas with reference to MAGE‐A and NY‐ESO‐1 expression in adenoid cystic carcinoma | |
Chiappori et al. | Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1193648 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1193648 Country of ref document: HK |
|
TR01 | Transfer of patent right |
Effective date of registration: 20200326 Address after: Shinka ha Patentee after: Oenkestm Pte Ltd Address before: Eberne, Mauritius Patentee before: ONCOSTEM DIAGNOSTICS PVT. Ltd. |
|
TR01 | Transfer of patent right |